covishield and covaxin. Covishield and Covaxin are two vaccines developed to combat COVID-19, and they have some key differences:
Developer and Manufacturer:
Covishield: Developed by Oxford University and AstraZeneca, and manufactured by the Serum Institute of India.
Covaxin: Developed and manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
Vaccine Type:
Covishield: A viral vector vaccine, using a modified adenovirus (a common cold virus) to deliver the genetic code for the spike protein of the SARS-CoV-2 virus, prompting the immune system to respond.
Covaxin: An inactivated virus vaccine, which uses a killed version of the coronavirus to stimulate an immune response without causing the disease.
Dosage Interval:
Covishield: Administered in two doses, with an interval of 4 to 12 weeks between doses.
Covaxin: Also administered in two doses, but with a shorter interval of 4 to 6 weeks between doses.
Storage Requirements:
Covishield: Can be stored at 2-8 degrees Celsius, similar to a standard refrigerator.
Covaxin: Also requires storage at 2-8 degrees Celsius, making it suitable for existing vaccine distribution infrastructure.
Efficacy:
Covishield: Clinical trials showed efficacy ranging from approximately 70% to 90% depending on the dosing regimen.
Covaxin: Clinical trials demonstrated an efficacy of around 78%.
Side Effects:
Both vaccines have shown similar side effects, including pain at the injection site, mild fever, fatigue, and headache. Serious side effects are rare.
Both vaccines have been widely used in India and other countries, contributing significantly to the global effort to control the COVID-19 pandemic.
Covishield :
Covishield is the name given to the AstraZeneca/Oxford University COVID-19 vaccine in India. It is produced by the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume. Covishield is a viral vector vaccine, meaning it uses a modified version of a different virus (a chimpanzee adenovirus) to deliver genetic material from the SARS-CoV-2 virus into human cells, prompting an immune response.
Key points about Covishield include:
Efficacy: Clinical trials have shown that Covishield has an efficacy rate of around 70% after the first dose, which increases with the second dose.
Storage: It can be stored at standard refrigerator temperatures (2-8 degrees Celsius), making it easier to distribute, especially in regions without advanced cold chain infrastructure.
Dosage: The vaccine is administered in two doses, typically 4 to 12 weeks apart.
Covishield has been a crucial part of vaccination campaigns in many countries, especially in low- and middle-income nations, due to its relatively low cost and easier storage requirements.
Covishield is the name given to the AstraZeneca/Oxford University COVID-19 vaccine in India. It is produced by the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume. Covishield is a viral vector vaccine, meaning it uses a modified version of a different virus (a chimpanzee adenovirus) to deliver genetic material from the SARS-CoV-2 virus into human cells, prompting an immune response.
Key points about Covishield include:
Efficacy: Clinical trials have shown that Covishield has an efficacy rate of around 70% after the first dose, which increases with the second dose.
Storage: It can be stored at standard refrigerator temperatures (2-8 degrees Celsius), making it easier to distribute, especially in regions without advanced cold chain infrastructure.
Dosage: The vaccine is administered in two doses, typically 4 to 12 weeks apart.
Covishield has been a crucial part of vaccination campaigns in many countries, especially in low- and middle-income nations, due to its relatively low cost and easier storage requirements.
Covaxin:
Covaxin is an inactivated virus COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). Here's a detailed overview:
Type: Covaxin is an inactivated virus vaccine, meaning it uses a killed version of the virus to stimulate an immune response without causing the disease.
Efficacy: Clinical trials have demonstrated an efficacy rate of around 78% to 81% against symptomatic COVID-19.
Storage: Similar to Covishield, Covaxin can be stored at standard refrigerator temperatures (2-8 degrees Celsius), facilitating easier distribution.
Dosage: The vaccine is administered in two doses, with the second dose typically given 4 weeks after the first.
Safety: Covaxin has been shown to be safe with a favorable safety profile, with side effects generally being mild and temporary, such as pain at the injection site, fatigue, and fever.
Approval and Use: Covaxin received emergency use authorization in India in January 2021 and has since been approved in several other countries. It has been a critical part of India's vaccination campaign, particularly valued for its indigenous development and production.
Covaxin's inactivated virus approach is a traditional method used in vaccines, which has a well-established safety record and robust immune response, contributing to its acceptance and use in various vaccination programs.
